Esperion Therapeutics, Inc. (ESPR) |
|
1.6 0.04 (2.56%)
|
03-24 16:00 |
|
Open: |
1.54 |
Pre. Close: |
1.56 |
|
High:
|
1.74 |
Low:
|
1.52 |
|
Volume:
|
8,100,446 |
Market Cap:
|
123(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:25:44 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 5.43 One year: 7.88 |
| Support: |
Support1: 1.25 Support2: 1.04 |
| Resistance: |
Resistance1: 4.65 Resistance2: 6.75 |
| Pivot: |
3.18  |
| Moving Average: |
MA(5): 1.53 MA(20): 3.93
MA(100): 6.07 MA(250): 6.3 |
| MACD: |
MACD(12,26): -1.2 Signal(9): -1 |
| Stochastic oscillator: |
%K(14,3): 5.6 %D(3): 4.9 |
| RSI: |
RSI(14): 16.3 |
| 52-week: |
High: 8.86 Low: 1.25 |
| Average Vol(K): |
3-Month: 3,733 (K) 10-Days: 11,522 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ESPR ] has closed above bottom band by 24.2%. Bollinger Bands are 212.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.74 - 1.75 |
1.75 - 1.76 |
|
Low:
|
1.5 - 1.51 |
1.51 - 1.52 |
|
Close:
|
1.59 - 1.6 |
1.6 - 1.61 |
|
Company Description |
|
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. |
Headline News |
Thu, 23 Mar 2023
Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound? - Yahoo Entertainment
Wed, 22 Mar 2023
2023-03-22 | NDAQ:ESPR | Press Release | Esperion Therapeutics ... - Stockhouse
Mon, 20 Mar 2023
Analyst Rating: Will Esperion Therapeutics Inc (ESPR) Stock Outperform the Market? - InvestorsObserver
Mon, 20 Mar 2023
Q1 2023 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ ... - MarketBeat
Fri, 17 Mar 2023
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus ... - MarketBeat
Fri, 17 Mar 2023
Is Esperion Therapeutics Inc (ESPR) Stock Worth a Buy Friday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
77 (M) |
| Shares Float |
66 (M) |
|
% Held by Insiders
|
0.9 (%) |
|
% Held by Institutions
|
99.3 (%) |
|
Shares Short
|
17,250 (K) |
|
Shares Short P.Month
|
18,850 (K) |
Stock Financials |
|
EPS
|
-1.26 |
|
EPS Est Next Qtl
|
-1.79 |
|
EPS Est This Year
|
-7.29 |
|
EPS Est Next Year
|
-5.6 |
|
Book Value (p.s.)
|
-4.35 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-237.9 |
|
Return on Assets (ttm)
|
-35.7 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
22.2 |
|
Gross Profit (p.s.)
|
-0.92 |
|
Sales Per Share
|
0.98 |
|
EBITDA (p.s.)
|
-2.34 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-175 (M) |
|
Levered Free Cash Flow
|
-136 (M) |
Stock Valuations |
|
PE Ratio
|
-1.27 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
-0.37 |
|
Price to Sales
|
1.62 |
|
Price to Cash Flow
|
-0.71 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
